Introduction to Breast Cancer: TAILORx Recap

TL;DR

The new breast cancer staging system incorporates genomic tests, which provide additional information about tumor biology and prognosis.

Transcript

welcome back to an introduction to breast cancer I'm dr. anis Jaguar I just returned from the American Society of Clinical Oncology meeting in Chicago this year and I wanted to share with you some updates because they really impact what we've been talking about in this course now many of you will remember from the last time I gave you an update ear... Read More

Key Insights

• 👶 The new breast cancer staging system incorporates genomic tests, shifting the focus towards tumor biology and prognosis.
• 💁 Genomic tests, such as Oncotype DX, provide valuable information about the response to endocrine therapy and the potential benefit of chemotherapy.
• 😘 Patients with a low recurrence score on genomic tests have a good prognosis and respond well to endocrine therapy alone.
• 💯 Most patients in the intermediate recurrence score range do not benefit from chemotherapy, except for younger women with a higher recurrence score.

Questions & Answers

Q: What changes were made to the breast cancer staging system?

The new staging system incorporates genomic tests, providing information about tumor biology, hormone receptor status, and HER2 positivity or negativity.

Q: What is the significance of genomic tests in breast cancer prognosis?

Genomic tests, such as Oncotype DX, can predict the 10-year distant disease-free survival rate and help determine whether patients will respond better to endocrine therapy or chemotherapy.

Q: Are there any groups of breast cancer patients who do not benefit from chemotherapy?

Patients with a low recurrence score (0-10) on genomic tests, regardless of tumor size or node involvement, benefit from endocrine therapy alone. Additionally, most patients with an intermediate recurrence score (11-25) do not benefit from chemotherapy, except for younger women with a higher recurrence score.

Q: What are the implications for treatment decisions based on genomic test results?

Patients with a low recurrence score can opt for endocrine therapy alone, while those with a high recurrence score (above 25) may benefit from the addition of chemotherapy. Intermediate recurrence score patients should consider factors such as age to determine the necessity of chemotherapy.

Summary & Key Takeaways

• The breast cancer staging system has been updated to include genomic tests, such as Oncotype DX, which analyze genes to determine prognosis.

• For hormone receptor positive, HER2 negative, and node negative tumors, a low recurrence score on genomic tests indicates a low risk and a good response to endocrine therapy alone.

• The Taylor rx trial showed that most patients with an intermediate recurrence score between 11 and 25 do not benefit from the addition of chemotherapy to endocrine therapy, except for younger women with a higher recurrence score.